Ignite Creation Date:
2024-05-06 @ 7:20 PM
Last Modification Date:
2024-10-26 @ 3:05 PM
Study NCT ID:
NCT05978726
Status:
COMPLETED
Last Update Posted:
2023-08-07
First Post:
2023-07-31
Brief Title:
Ticagrelor Versus Clopidogrel for CMD in Patients With AMI A Retrospective Study Based on the Angio-IMR
Sponsor:
Second Affiliated Hospital School of Medicine Zhejiang University
Organization:
Second Affiliated Hospital School of Medicine Zhejiang University
Study Overview
Official Title:
Ticagrelor Versus Clopidogrel for Coronary Microvascular Dysfunction in Patients With Acute Myocardial Infarction A Retrospective Study Based on the Angiography-derived Index of Microcirculatory Resistance
Status:
COMPLETED
Status Verified Date:
2023-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Coronary microvascular dysfunction CMD is increasingly recognized as an important indicator for long-term prognosis in patients with acute myocardial infarction AMI The angiography-derived index of microcirculatory resistance angio-IMR is a novel guidewire-free measure for CMD in patients with AMI Ticagrelor has recently been suggested to have additional benefits on coronary microcirculation beyond its antiplatelet effect This study was designed to compare the protective effects of ticagrelor and clopidogrel on CMD and prognostic impact in patients with AMI using the angio-IMR as a novel assessment tool
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None